John Haanen

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


9 publications

In press
 
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
Blank C.U., Lucas M.W., Scolyer R.A., van de Wiel B.A., Menzies A.M., Lopez-Yurda M., Hoeijmakers L.L., Saw RPM, Lijnsvelt J.M., Maher N.G. et al. The New England journal of medicine. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2A38E708B018]
2024
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.
Verheijden R.J., Burgers F.H., Janssen J.C., Putker A.E., Veenstra SPGR, Hospers GAP, Aarts MJB, Hehenkamp K.W., Doornebosch VLE, Verhaert M. et al., 2024/08. European journal of cancer, 207 p. 114172. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB4D3ADF8F4A]
 
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Pal S.K., Tran B., Haanen JBAG, Hurwitz M.E., Sacher A., Tannir N.M., Budde L.E., Harrison S.J., Klobuch S., Patel S.S. et al., 2024/07/01. Cancer discovery, 14 (7) pp. 1176-1189. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_380D2196CD9C]
 
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.
Chalabi M., Verschoor Y.L., Tan P.B., Balduzzi S., Van Lent A.U., Grootscholten C., Dokter S., Büller N.V., Grotenhuis B.A., Kuhlmann K. et al., 2024/06/06. The New England journal of medicine, 390 (21) pp. 1949-1958. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6BBA7AFF15CD]
 
Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.
Haanen J., Los C., Phan G.Q., Betof Warner A., 2024/06. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 44 (3) pp. e431608. Peer-reviewed.
[DOI][Pmid][serval:BIB_D7A4B8D24794]
 
Melanoma neoantigen vaccines: Are we getting more personal now?
Latifyan S., Haanen J.B., 2024/04/12. Med, 5 (4) pp. 288-290. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_362339C5E2F1]
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.
Verkerk K., Geurts B.S., Zeverijn L.J., van der Noort V., Verheul HMW, Haanen JBAG, van der Veldt AAM, Eskens FALM, Aarts MJB, van Herpen CML et al., 2024/04. The Lancet regional health. Europe, 39 p. 100875. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FB1F09F33DB5]
 
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.
Castenmiller S.M., Kanagasabesan N., Guislain A., Nicolet B.P., van Loenen M.M., Monkhorst K., Veenhof AAFA, Smit E.F., Hartemink K.J., Haanen JBAG et al., 2024. Oncoimmunology, 13 (1) p. 2392898. Peer-reviewed.
[DOI][Pmid][serval:BIB_4F0F8DC467FB]
 
Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma.
Los C., Klobuch S., Haanen JBAG, 2024. Cancer journal, 30 (2) pp. 113-119. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2ECDF6921A25]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University